Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Phase of Trial: Phase IV
Latest Information Update: 04 May 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-XPEDITION
- 19 Dec 2018 Planned End Date changed from 1 Jun 2023 to 1 May 2024.
- 19 Dec 2018 Planned primary completion date changed from 1 Jun 2018 to 1 May 2020.
- 10 Jul 2017 Planned number of patients changed from 2500 to 4000.